4Stevens AM, Johnson FC. A new eruptive fever associated with stomatitis and opthalmia: report of two cases in children[J]. Am J Dis Child, 1922, 24 (6) : 526-533.
5Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis [J]. N Engl J Med, 1995, 333 (24) : 1600-1607.
6Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel [J]. J Am Acad Dermatol, 2008, 58 (1) : 25-32.
7Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. the EuroSCAR-study[J]. J Invest Dermatol, 2008, 128 (1): 35-44.
8Jeung Y J, Lee JY, Oh M J, et al. Comparison of the causes and clinical features of drug rash with eosinophilia and systemic symptoms and Stevens-Johnson syndrome [J]. Allergy Asthma Immunol Res, 2010, 2 (2) : 123-126.
9Sethuraman G, Sharma VK, Pahwa P, et al. Causative drugs and clinical outcome in Stevens Johnson syndrome (SJS),toxic Epidermal Necrolusis (TEN), and SJS-TEN overlap in children[J]. Indian J Dermatol, 2012, 57 (3) : 199-200.
10Hung SI, Chung WH, Liou LB, et al. HLAB*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol[J]. Proc Nat Acad Sci USA, 2005, 102 (11): 4134-4139.
